Technical metrics like "accuracy" are often the wrong measure for ML projects and can mismanage expectations. To achieve success, projects must be evaluated using business KPIs like profit, savings, or ROI. This aligns data science with business goals and reveals the true value of imperfect predictions.

The most common failure in AI implementation is treating it as a technology project to automate existing workflows. True success requires a transformational mindset, using AI as a catalyst to completely redesign how work gets done and how human and AI agents collaborate.

The 85% AI project failure rate isn't a technology problem. It stems from four business and process issues: failing to identify a narrow use case, using data that isn't clean or ready, not defining success and risk, and applying deterministic Agile methods to probabilistic AI development.

Many organizations excel at building accurate AI models but fail to deploy them successfully. The real bottlenecks are fragile systems, poor data governance, and outdated security, not the model's predictive power. This "deployment gap" is a critical, often overlooked challenge in enterprise AI.

Teams often fall into the trap of optimizing for model accuracy, a metric popularized by academic settings like Kaggle. In business, this is misleading. A highly accurate model might be too passive and miss opportunities. The focus must shift from pure accuracy to real-world business outcomes and ROI.

Many AI projects become expensive experiments because companies treat AI as a trendy add-on to existing systems rather than fundamentally re-evaluating the underlying business processes and organizational readiness. This leads to issues like hallucinations and incomplete tasks, turning potential assets into costly failures.

Much like the big data and cloud eras, a high percentage of enterprise AI projects are failing to move beyond the MVP stage. Companies are investing heavily without a clear strategy for implementation and ROI, leading to a "rush off a cliff" mentality and repeated historical mistakes.

The primary reason most pharmaceutical AI projects fail to deliver value is not technical limitation but strategic failure. Organizations become obsessed with optimizing algorithms while neglecting the foundational blueprint that connects AI investment to measurable business outcomes and operational readiness.

Stalled AI projects often stem from cultural issues. Leaders rush for big wins instead of adopting an experimental "build to learn" mindset. They fail to address poor data quality and the organizational fear that leads to automating old processes instead of innovating new ones.